(Reuters) - British drugmaker GSK said it was "well positioned" to respond to any potential impact from sector-specific tariffs if they were implemented and it had identified options within its supply chain and productivity initiatives to mitigate any hit.

U.S. President Donald Trump this month reiterated plans for a "major" tariff on pharmaceutical imports, but he has not said when and by how much he plans to raise levies on pharmaceutical imports which could threaten an interwoven global supply chain and raise U.S. drug costs by $51 billion annually.

Still, GSK reaffirmed its 2025 forecasts on Wednesday after higher first-quarter turnover of 7.52 billion pounds ($10.07 billion) and core profit of 44.9 pence per share surpassed analysts' expectations.

It was not immediately clear whether the drugmaker's outlook had factored in the impact from tariffs and the company did not give further details on the options identified.

In February, GSK had lifted its long-term sales target to over 40 billion pounds by 2031, but uncertainties around U.S. tariffs on pharmaceutical imports and the Trump administration's policies on vaccines and HIV prevention loom large on drugmakers in the near term.

($1 = 0.7468 pounds)